Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
35.1M
-
Shares change
-
+401K
-
Total reported value, excl. options
-
$82.8M
-
Value change
-
+$1.03M
-
Put/Call ratio
-
0.39
-
Number of buys
-
28
-
Number of sells
-
-17
-
Price
-
$2.36
Significant Holders of GLYCOMIMETICS INC - Common Stock, par value $0.001 per share (GLYC) as of Q4 2023
66 filings reported holding GLYC - GLYCOMIMETICS INC - Common Stock, par value $0.001 per share as of Q4 2023.
GLYCOMIMETICS INC - Common Stock, par value $0.001 per share (GLYC) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.1M shares
.
Largest 10 shareholders include BVF INC/IL (9.54M shares), Artal Group S.A. (8.59M shares), NEA Management Company, LLC (4.76M shares), Octagon Capital Advisors LP (3M shares), VANGUARD GROUP INC (2.42M shares), AXA S.A. (1.59M shares), GOLDMAN SACHS GROUP INC (919K shares), BlackRock Inc. (735K shares), ACADIAN ASSET MANAGEMENT LLC (541K shares), and GEODE CAPITAL MANAGEMENT, LLC (479K shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.